Technology | Vascular Closure Devices | August 03, 2016

FDA Clears Bioresorbable Vascular Closure Device

Rex medical, Closer Vascular Sealing System, VSS, vascular closure, bioresorbable vascular closure device

A close up view of the Rex Medical Closer Vascular Sealing System components.

Rex medical, Closer Vascular Sealing System, VSS, vascular closure, bioresorbable vascular closure device
Rex medical, Closer Vascular Sealing System, VSS, vascular closure, bioresorbable vascular closure device

August 3, 2016 — The U.S. Food and Drug Administration (FDA) has granted market clearance to Rex Medical’s bioresorbable Closer Vascular Sealing System (VSS) to achieve rapid hemostasis of femoral artery catheterizations. 

The vascular closure device consists of an insertion sheath, dilator and an implant contained in a delivery system. It uses a patch placed against the artery wall and is secured on the outside of the vessel by an an attached suture connected to two spheres. The suture brings the patch and spheres together. The patch and spheres are made of polylactide-co-glycolide acid co-polymer. The suture is made of Polydiaxanone. The components of the device are designed to dissolve inside the body after they serve their purpose. 

Doctors put the sheath into the artery through the hole in the artery wall. They then use the delivery system to push the patch out of the end of the sheath into the artery. As the doctor pulls the system out of the artery, the patch sits against the arterial wall. Once this happens, the spheres are uncovered in the space outside the artery. Finally, the patch and spheres are “cinched” together such that the device sandwiches the arterial wall. This stops the blood flow. Later, the body absorbs the patch, sutures and spheres after the wound heals.

The system helps enable faster ambulation of the patient, reducing recovery and nursing time.

For more information: rexmedical.com

Related Content

Videos | Cath Lab | July 15, 2020
Richard Botto, CVT, RCSA, chief cardiovascular technologist, division of cardiology, cardiac cath lab, offers an over
Videos | Cath Lab | July 13, 2020
The Vieussens’ arterial ring (VAR) is a connection between the conus artery and the left anterior descending (LAD) co
News | Cath Lab | July 06, 2020
July 6, 2020 — Black patients who undergo percutaneous coronary intervention (PCI) are at an increased risk for major
TCT cancels in-person meeting and goes virtual due to COVID-19
News | Cath Lab | May 27, 2020
May 27, 2020 — To ensure the health and safety of all attendees due to the ongoing COVID-19 (SARS-CoV-2) pandemic, th
Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, or nil per os (NPO), as there are no current standardized fasting protocols, but the CHOWNOW study found patients do not need to fast and will have similar outcomes. #SCAI2020
Feature | Cath Lab | May 18, 2020
May 18, 2020 – Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, o
Ehtisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiography and Interventions (SCAI) and chief, Division of Cardiovascular Medicine at UC San Diego Medical Center,
Podcast | Cath Lab | May 13, 2020
This podcast is an interview with Ehtisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiograp
Nuance Communications Inc. introduced Nuance Cardiovascular CAPD, a new computer-assisted physician documentation (CAPD) solution designed to help cardiologists improve the quality of complex documentation and the accuracy of reimbursement for cardiac catheterization procedures. The Nuance Cardiovascular CAPD solution is available through a partnership with ZHealth for this solution, which is based on patented algorithms built with ZHealth’s interventional documentation and coding expertise.
News | Cath Lab | January 31, 2020
January 29, 2020 – Nuance Communications Inc.